<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01195441</url>
  </required_header>
  <id_info>
    <org_study_id>EUDRACTNUMMER 2009-017833-23</org_study_id>
    <secondary_id>2009-017833-23</secondary_id>
    <nct_id>NCT01195441</nct_id>
  </id_info>
  <brief_title>Prediction and Prevention of Preeclampsia by First Trimester Ultrasound</brief_title>
  <acronym>Screen-tox</acronym>
  <official_title>Prediction and Prevention of Preeclampsia by First Trimester Ultrasound</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the Fetal Medicine Foundation algorithm for
      individual risk calculation for preeclampsia (PE) and pregnancy induced hypertension (PIH) is
      suitable to identify women in high risk of developing these diseases in a Norwegian
      population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been shown that low dose acetylsalicylic acid (ASA) in pregnancy reduces adverse
      outcome of pregnancy in women that have high risk of developing preeclampsia (PE). It is a
      challenge for the clinician to identify the high risk women. Doppler blood flow measurements
      in uterine arteries in second trimester have been shown useful to predict the development of
      the disease but prophylactic treatment with ASA from this point in pregnancy has not been
      proven effective. Fetal Medical Foundation has developed an algorithm that calculates
      individual risks for PE/ PIH based on Doppler blood flow measurements and anamnestic
      information.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2010</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of preeclampsia</measure>
    <time_frame>september 2012</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Onset time of preeclampsia</measure>
    <time_frame>September 2012</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gestational age at delivery</measure>
    <time_frame>September 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of induction of deliveries due to preeclampsia</measure>
    <time_frame>September 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of instrumental deliveries due to preeclampsia</measure>
    <time_frame>September 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perinatal morbidity</measure>
    <time_frame>September 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal morbidity</measure>
    <time_frame>September 2012</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">602</enrollment>
  <condition>Preeclampsia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples Urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant

          -  Nulliparous

          -  Para 1+ with previous preeclampsia or gestational hypertension

          -  last menstrual period (LMP) pregnancy length at inclusion &lt; 13 weeks

          -  Residence in Trondheim + 8 surrounding municipalities

        Exclusion Criteria:

          -  Pregnancy length &gt; 13+6 weeks (CRL &gt; 85 mm)

          -  Twins

          -  Missed abortion

          -  Fetal anomaly
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ragnhild B Skraastad, Cand Med</last_name>
    <role>Principal Investigator</role>
    <affiliation>LBK, NTNU, National Center for Fetal Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kjell Aa Salvesen, Dr Med</last_name>
    <role>Study Director</role>
    <affiliation>LBK, NTNU, National Center for Fetal Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harm-Gerd K Blaas, Dr Med</last_name>
    <role>Study Director</role>
    <affiliation>LBK, NTNU, National Center for Fetal Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Center for Fetal Medicine, St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006 Trondheim</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Skråstad RB, Hov GG, Blaas HG, Romundstad PR, Salvesen KÅ. Risk assessment for preeclampsia in nulliparous women at 11-13 weeks gestational age: prospective evaluation of two algorithms. BJOG. 2015 Dec;122(13):1781-8. doi: 10.1111/1471-0528.13194. Epub 2014 Dec 4.</citation>
    <PMID>25471057</PMID>
  </results_reference>
  <results_reference>
    <citation>Skråstad RB, Hov GG, Blaas HG, Romundstad PR, Salvesen KÅ. A prospective study of screening for hypertensive disorders of pregnancy at 11-13 weeks in a Scandinavian population. Acta Obstet Gynecol Scand. 2014 Dec;93(12):1238-47. doi: 10.1111/aogs.12479. Epub 2014 Sep 17.</citation>
    <PMID>25146367</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2010</study_first_submitted>
  <study_first_submitted_qc>September 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2010</study_first_posted>
  <last_update_submitted>February 10, 2017</last_update_submitted>
  <last_update_submitted_qc>February 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preeclampsia</keyword>
  <keyword>Doppler ultrasound</keyword>
  <keyword>First trimester</keyword>
  <keyword>Acetylsalicylic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

